AVITA Medical, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of AVITA Medical, Inc.'s 2026 Annual Meeting of Stockholders, held via remote webcast on June 3, 2026. The record date for the meeting was April 9, 2026, with 30,776,689 shares outstanding. A quorum was established with 15,592,447 shares voted.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The report focuses exclusively on corporate governance actions and shareholder voting outcomes.
Material Changes and Voting Results
- Director Elections: All seven nominees were elected to the Board of Directors. Cary Vance received the highest "For" vote count (11,176,792), while Jeremy Curnock Cook received the lowest (10,700,424).
- Auditor Ratification: Stockholders ratified Grant Thornton LLP as the independent registered public accounting firm for the year ending December 31, 2026.
- Director Compensation Increase: The aggregate annual cash fee pool for non-executive directors was approved for an increase from $750,000 to $900,000 per annum.
- Equity Grants to Directors:
- Annual Grants: Approved for six non-executive directors, totaling 22,214 restricted stock units (RSUs) and 16,133 stock options per director.
- Initial Grants: Approved for Dr. Michael Tarnoff (26,250 RSUs and 19,063 options) and Joseph Woody (40,547 RSUs and 29,446 options).
- Executive Compensation: Stockholders approved the non-binding advisory vote on Named Executive Officer compensation and voted to hold future advisory votes annually.
- Warrant Issuance: Approved the issuance of warrants covering up to 650,000 shares of Common Stock to Perceptive Credit Holdings V, LP, pursuant to a credit agreement dated January 13, 2026.
- Equity Issuance Authority: Approved a special resolution to issue equity securities up to an additional 10% of issued capital beyond the standard 15% annual listing limit under ASX Listing Rule 7.1A.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The primary contingency noted is the authorization to issue warrants and additional equity securities, which may result in future dilution.
Key Facts for Investor Verification
- Verify the terms of the credit agreement with Perceptive Credit Holdings V, LP regarding the 650,000 warrant issuance.
- Review the definitive Proxy Statement (Schedule 14A filed April 22, 2026) for detailed terms of the director equity grants and the increased cash fee pool.
- Monitor the impact of the approved 10% additional equity issuance authority on future capital structure and potential dilution.
- Confirm the voting breakdown for the director elections, noting that while all were elected, vote counts varied among nominees.